Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312. SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally. The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations. The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy. |
Liquor sales in movie theaters, toAs earnings season rolls into its heart, hopes rise for broader gainsMeta's newest AI model beats some peers. But its ampedJets might have a tough call to make between a playmaker or protection at No. 10 in the NFL draftTom Schwartz rates Las Vegas kiss with Scheana Shay a FIVE as he brands it 'weird': 'So platonic'Civilian interrogator defends work at Abu Ghraib, tells jury he was promotedThe Arizona Coyotes are officially headed to Salt Lake CityHilarious voice to text messages that'll make you wish people still used landlinesQuentin Tarantino SCRAPS plans for his final film The Movie Critic which had Brad Pitt set to starJets might have a tough call to make between a playmaker or protection at No. 10 in the NFL draft